Patrick Daly

DocwireNews

According to a study published in Annals of Hematology, although several therapies have been approved for use in immune thrombocytopenic purpura (ITP) after first-line treatment with splenectomy and rituximab, the effect of these agents on bleeding risk is underexplored. Investigators, led by Inbar Cohen, conducted a meta-analysis on recently-approved targeted therapies and found that &ldquo;targeted therapies for ITP increase platelet counts, decrease bleeding events, and show a trend towards lower mortality without increased toxicity,&rdquo; compared to placebo.The meta-analysis included 752 adult patients from six randomized controlled trials for recent targeted therapies. Four targeted therapies of interest were selected from recently published professional treatment guidelines: one tyrosine kinase inhibitor and three thrombopoietin receptor agonists. The primary efficacy outcomes included platelet recovery to 50,000/&micro;L or more, survival, and major and minor bleeding events. Investigators also calculated the odds ratios (ORs) for all adverse events recorded in the included articles.According to Cohen and colleagues, targeted therapies for ITP were associated with a significantly lower risk for major bleeding (OR = 0.43; 95% confidence interval [CI], 0.21&ndash;0.91) and minor bleeding (OR = 0.66; 95% CI, 0.49&ndash;0.97) compared with placebo, as well as numerically lower mortality rates (OR = 0.24; 95% CI, 0.76 &ndash; 2.67).Given the significant and numerical advantages seen in the analysis of targeted therapies for ITP compared to placebo&mdash;without increased toxicity&mdash;the authors proposed that their results support the use of these therapies as second-line treatment for patients with ITP.

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

Bleeding Risk With Targeted Therapies for Immune Thrombocytopenic Purpura

According to a study published in Annals of Hematology, although several therapies have been approved for use in immune thrombocytopenic purpura (ITP) after first-line ...

Bleeding Risk with Targeted Therapies for Immune Thrombocytopenic Purpura

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe